Eli Lilly and Company (LLY)vsOrganiGram Holdings Inc (OGI)
LLY
Eli Lilly and Company
$1,433.55
-0.82%
HEALTHCARE · Cap: $1.27T
OGI
OrganiGram Holdings Inc
$0.83
-0.65%
HEALTHCARE · Cap: $117.60M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 27865% more annual revenue ($86.46B vs $309.18M). LLY leads profitability with a 31.9% profit margin vs 28.0%. OGI trades at a lower P/E of 1.9x. LLY earns a higher WallStSmart Score of 74/100 (B).
LLY
Strong Buy74
out of 100
Grade: B
OGI
Buy58
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 51.2%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 49.4% year-over-year
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 51.2%. Revenue growth of 38.6% demonstrates continued momentum.
Bull Case : OGI
The strongest argument for OGI centers on P/E Ratio, Price/Book, Revenue Growth. Profitability is solid with margins at 28.0% and operating margin at -2.2%. Revenue growth of 49.4% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.3x leaves little room for execution misses.
Bear Case : OGI
The primary concerns for OGI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
OGI carries more volatility with a beta of 1.98 — expect wider price swings.
OGI is growing revenue faster at 49.4% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (74/100 vs 58/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →OrganiGram Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organigram Holdings Inc. produces and sells cannabis and cannabis-derived products in Canada. The company is headquartered in Moncton, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?